Skip to main content
. Author manuscript; available in PMC: 2021 Jun 1.
Published in final edited form as: Cancer Prev Res (Phila). 2020 Sep 11;13(12):979–988. doi: 10.1158/1940-6207.CAPR-20-0186

Figure 3. In vivo progression of MYC driven HG-PIN is attenuated by chemical inhibition of EZH2.

Figure 3.

Genetically engineered mice that develop prostate adenocarcinoma driven by MYC overexpression (Hi-MYC) were treated with (A) 0.5% CMC (Control, n=4) or EPZ0011989 (n=4) or (B) 5% DMSO (Control, n=8) or DZNep (n=10). DZNep significantly attenuates progression of MYC driven HG-PIN. EPZ0011989 also attenuated progression but did not reach statistical significance. Immunohistochemical analysis of tumor tissue indicates that both DZNep and EPZ0011989 significantly reduce tumor H3K27me3 levels and tumor proliferation as assessed by Ki67. Scale bar = 50μm.